Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 261-271

  Perez, Edith A ^a   Patel, Tejal ^a   Moreno Aspitia, Alvaro ^a  

^a MAYO CLINIC   (United States)

Author keywords

Basal like; Breast cancer; Epothilone; ER PR HER2 negative; Ixabepilone; Triple negative

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AGO 14699; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUOROURACIL; GEMCITABINE; IXABEPILONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; EPOTHILONES; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77953025896     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0824-0     Document Type: Review

References (60)

1. Brennan DJ, O'Brien SL, Fagan A et al (2005) Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 5:1069-1083 (Pubitemid 41170036)
2. Kaklamani V (2006) A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX. Expert Rev Mol Diagn 6: 803-809
3. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244 (Pubitemid 46291713)
4. Altmann KH, Wartmann M, O'Reilly T (2000) Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470: M79-M91 (Pubitemid 30229922)
5. Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7: 1429-1437 (Pubitemid 32708699)
6. Jordan MA, Miller H, Ray A, et al (2006) The Pat-21 breast cancer model derived from, a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered βtubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 47:73 (abstract LB-280)
7. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
8. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423 (Pubitemid 36842560)
9. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502 (Pubitemid 43854964)
10. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657 (Pubitemid 46631305)
11. Finnegan TJ, Carey LA (2007) Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3(1): 55-63
12. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374 (Pubitemid 39100473)
13. Siziopikou KP, Cobleigh M (2007) The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16: 104-107
14. Korsching E, Packeisen J, Agelopoulos K et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Investig 82: 1525-1533 (Pubitemid 35332911)
15. Bergamaschi A, Kim YH, Wang P et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033-1040 (Pubitemid 44435537)
16. Wang ZC, Lin M, Wei LJ et al (2004) Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64: 64-71. (Pubitemid 38114083)
17. Hartman AR, Ford JM. (2003) BRCAl. and p53: compensatory roles in DNA repair. J Mol Med 81: 700-707
18. Harris LN, Broadwater G, Lin NU et al (2006) Molecular subtypes of breast cancer in relation to paclitaxel response, outcomes in women with metastatic disease: results from CALGB, Breast Cancer Res 8: R66
19. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2007) BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12: 142-150
20. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96: 1659-1668 (Pubitemid 39585635)
21. Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271 (Pubitemid 43117611)
22. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32 (Pubitemid 46120191)
23. Osbourne CR, Kannan L, Ashfaq R et al (2005) Clinical and pathological characterization of basal-like breast cancer. Breast Cancer Res Treat 118 (abstract)
24. Rodriguez-Pinilla SM, Sarrio D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12: 1533-1539
25. Tsuda H, Takarabe T, Hasegawa F et al (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24: 197-202 (Pubitemid 30078708)
26. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685 (Pubitemid 41170290)
27. Liedtke C, Mazouni C, Hess KR et al (2007) Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol 25(18S): 10519 (abstract)
28. Moynahan ME, Cui TY, Jasin M (2001) Homology-directed DNA repair, mitomycin C resistance, and chromosome stability is restored with correction of BRCA1 mutation. Cancer Res 61: 4842-4850
29. Bhattacharyya A, Ear US, Holler BH et al (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899-23903 (Pubitemid 30624678)
30. Wang S, Yang H, Tong F et al (2009) Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho 36(2): 255-258
31. O'Shaughnessy J, Osborne C, Pippen J et al (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARPl) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27: 18s
32. Corkery B, O'Donovan N, Clynes M, Crown J (2007) Epidermal growth factor receptor (EGFR) inhibition in triple-negative breast cancer (BrCa). J Clin Oncol 25(18): 14071 (abstract)
33. Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238 (Pubitemid 46424242)
34. Miller KD (2005) Angiogenic therapy for breast cancer.In: 28th annual San Antonio breast cancer symposium, San Antonio, TX, USA, 8-11 Dec
35. Altundag K, Harputluoglu H, Aksoy S, Gullu IH (2007) Potential chemotherapy options in the triple negative subtype of breast cancer. J Clin Oncol 25: 1294-1295 (Pubitemid 46640586)
36. Nogales E, Wolf SG, Khan IA, Ludueña RF, Downing KH (1995) Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature 375: 424-427
37. Giannakakou P, Gussio R, Nogales R et al (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Nat Acad Sci 97(6): 2904-2909 (Pubitemid 30159270)
38. Kolman A (2005) Activity of epothilones. Curr Opin Investig Drugs 6: 616-622
39. Llombart-Cussac A, Baselga J, Manikhas E et al (2005) Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): preliminary efficacy and safety data. J Clin Oncol 23(16s): 586 (abstract)
40. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493 (Pubitemid 27289876)
41. Gradishar WJ (1997) Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11: 15-18 (Pubitemid 27357871)
42. Buzdar AU, Singletary SE, Theriault RL et al (1999) Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17: 3412-3417
43. Amat S, Bougnoux P, Penault-Llorca F et al (2003) Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88: 1339-1345 (Pubitemid 36606412)
44. Estevez LG, Cuevas JM, Anton A et al (2003) Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 9: 686-692 (Pubitemid 36182601)
45. Gradishar WJ, Wedam SB, Jahanzeb M et al (2005) Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 16: 1297-1304 (Pubitemid 41158474)
46. Baselga J, Zambetti M, Llombart-Cussac A et al (2009) Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 27: 526-534
47. Horak CE, Lee FY, Xu L, Galbraith S, Baselga J (2009) High βIII tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J Clin Oncol 27: 15s
48. Roché H, Perez E, Llombart-Cussac A et al (2006) Ixabepilone, an epothilone analog, is effective in ER-, PR-, HER2-negative (triple-negative) patients: data from neoadjuvant and metastatic breast cancer trials. Ann Oncol 17 (Suppl 9): ix97-ix98
49. Bunnell C, Vahdat L, Schwartzberg L et al (2008) Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8: 234-241 (Pubitemid 351962144)
50. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33): 5210-5217
51. Hortobagyi GN, Perez E, Vrdoljak E et al (2008) Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials. In: ASCO breast cancer symposium, Washington, DC, USA, 5-7 Sept
52. Rugo HS, Roche H, Thomas E, et al (2008) Ixabepilone plus capecitabine vs. capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. In: 31st Annual San Antonio Breast Cancer symposium, San Antonio, TX, USA, 10-14 Dec
53. Vahdat L, Bunnell C, Schwartzberg L et al (2006) Ixabepilone is effective in combination with capecitabine in ER-, PR-, HER2negative (triple-negative) patients pretreated with taxanes and anthracyclines: final results from a breast cancer exploratory program. Ann Oncol 17(Suppl 9): ix69-ix92 (abstract 159P)
54. IXEMPRA® (2009) Prescribing information. Bristol-Myers Squibb, Princeton
55. Zhou J, Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5: 65-71
56. Larkin JMG, Kaye SB (2006) Epothilones in the treatment of cancer, Expert Opin Investig Drugs 15(6): 691-702
57. Perez E, Pivot X, Vrdoljak E, et al (2008) A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. In: 31st annual San Antonio breast cancer symposium, San Antonio, TX, USA, 10-14 Dec
58. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, for the North Central Cancer Treatment Group (2009) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (NO531). Ann Oncol 20(3): 449-453
59. Yardley DA, Burris HA III, Simons L et al (2008) A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer 8(5): 425-431
60. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676